Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Head & Neck 1
2011-000391-34Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of afatinib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival. Started Jun 2011; status: completed.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-000391-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000391-34.